Ian Townsend

NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.

The Medical House Ltd. manufactures and develops surgical instrumentation and drug delivery products. The company operates two divisions Orthopedic and Drug Delivery Systems. The Orthopedic division designs, develops and manufactures instruments and devices for use in orthopedic surgery. The Drug Delivery Systems divisions manufactures and supplies the mhi-500 needle-free insulin delivery system. The company was founded by Ian Townsend in1988 and is headquartered in Sheffield, the United Kingdom.

NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.

Reset Certification Scheme Ltd. offers safety-enhancing, time and cost-saving products and tools for any organization that needs to bring third-party contractors onto their site. The company was founded by Gary Duce and is headquartered in Sheffield, the United Kingdom.

Townsend Investments Ltd (Townsend Investments) is venture capital firm is founded in 2013 by Ian Townsend. The firm is headquartered in Harrogate, UK.

Reset Certification Scheme Ltd. offers safety-enhancing, time and cost-saving products and tools for any organization that needs to bring third-party contractors onto their site. The company was founded by Gary Duce and is headquartered in Sheffield, the United Kingdom.

Reset Certification Scheme Ltd. offers safety-enhancing, time and cost-saving products and tools for any organization that needs to bring third-party contractors onto their site. The company was founded by Gary Duce and is headquartered in Sheffield, the United Kingdom.